The biologic basis for neuroblastoma heterogeneity and risk stratification.
about
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaLithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cellsNeuroblastomaSmall round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface moleculeSignificance and therapeutic value of miRNAs in embryonal neural tumorsThe zebrafish as a model for studying neuroblastomaCombined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High AccuracyIdentification of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation in association with neuroblastoma progressionCross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genesOptimization of liposomal topotecan for use in treating neuroblastoma.An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoringPreclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.Intermittent hypoxia effect on osteoclastogenesis stimulated by neuroblastoma cells.Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells.Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.Pax genes in embryogenesis and oncogenesis.Autophagy is associated with chemoresistance in neuroblastoma.BMCC1, which is an interacting partner of BCL2, attenuates AKT activity, accompanied by apoptosis.The role of chest computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma.The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressorChromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma.Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification.Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma.New Technologies for Diagnosing Pediatric Tumors Expert Opinion on Medical Diagnostics.Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.High-dose chemotherapy and autologous stem cell rescue in patients with high-risk stage 3 neuroblastoma: 10-year experience at a single center.Bcl6 is expressed in neuroblastoma: tumor cell type-specific expression predicts outcome.Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.Molecular characterization and classification of neuroblastoma.Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?The connections between neural crest development and neuroblastoma.
P2860
Q24186636-A0CC0FF5-B3BA-4B0A-8B8E-CD718E0EBE7BQ24200296-8F1989DB-B5AA-498F-86A5-E76B37B1354CQ24235309-1A2C52CC-0C00-47D5-AC9F-E42D70A07002Q24617423-65FF2CF1-FDE9-49F3-ACA7-889AC7B5CBF6Q24617733-D4800CD5-9D1B-4999-9C6D-58DAFA80A5A2Q24655582-23264689-E4D6-4988-8581-708EC7FF16F5Q26827171-7A2F515A-A27C-4119-A882-EF8608B1DAA7Q28070309-0F48880F-5526-49DE-86B2-81D9AC1696A2Q28546522-47FED829-6FBB-4299-BFC3-A068065EBABDQ30955037-F211283A-E75E-47E9-AAE4-583CB9D83153Q31113844-EA634D3F-4AE0-4FA8-8260-040DA537C813Q33275966-42317342-1764-4ECB-B1D7-D78BC4AFD1FAQ33494188-7BB479B4-9E1A-46D4-A31F-424FE2056882Q33775276-528299C5-0C42-4D30-9A73-7F568820ECA9Q33990542-0BA29629-7952-424B-8272-8CC637384FB7Q34055511-850DC03F-C055-4A4A-9244-6D862095E207Q34078699-9463E8F5-797C-417E-9CFF-0ED533D31A42Q34170335-6F1BF885-4F64-4054-9650-8692267182E8Q34200348-D51EACE1-8B08-4A87-A964-F85AEB04A8F2Q35097218-8A222BC1-7322-4154-BB3A-2D25983B42FEQ35609613-438E1157-8A4F-481C-9339-289BBA18CFE5Q35832541-C9E0EF21-DB37-45BD-88C3-CB463474EFA6Q35886629-CEFE22DE-A678-4325-AE18-9121AD2BC024Q36193465-86DA496C-F0F4-4EA4-995B-C0AA99B0378AQ36347152-2A511E51-6534-4BBC-9263-AAC3314CE020Q36411061-3A8F13B2-97FE-43DF-9126-83CE7D97CC21Q36517840-101BEB06-F5EA-404F-AD9E-82C5EE17150FQ36610830-8B0B5678-CF32-487B-8851-285AB5ED128DQ36614690-4392C08C-1757-46AB-B825-E53C5C3BA93CQ36874331-E27B8581-82A9-4AAD-8926-D3CD456549C8Q37035532-0315C465-2B01-4CCB-B034-06AD46016D86Q37238431-DF30C68D-4B70-4D51-ADF8-1DA855280A9EQ37284320-0901DDF7-AEF3-4575-BB27-EDA0D32B5895Q37284671-1BF242D6-9037-4E8E-9AEB-C4A2CE3AB03CQ37313694-3CAA6A59-0EAD-4A96-AF96-E3AF64FB4113Q37315226-F139E3BE-860E-42EF-AB6E-95757EB2EAEDQ37437735-82C082F7-E776-4D91-8007-122521233517Q37515355-B63A6738-8326-4D03-BDBD-5C0E2B08AB23Q37834445-E07A1C52-BA5C-49E9-A909-92993268F53CQ37836006-06A29DA8-9C11-4FD7-928E-7218E7D6A78B
P2860
The biologic basis for neuroblastoma heterogeneity and risk stratification.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The biologic basis for neuroblastoma heterogeneity and risk stratification.
@ast
The biologic basis for neuroblastoma heterogeneity and risk stratification.
@en
type
label
The biologic basis for neuroblastoma heterogeneity and risk stratification.
@ast
The biologic basis for neuroblastoma heterogeneity and risk stratification.
@en
prefLabel
The biologic basis for neuroblastoma heterogeneity and risk stratification.
@ast
The biologic basis for neuroblastoma heterogeneity and risk stratification.
@en
P1476
The biologic basis for neuroblastoma heterogeneity and risk stratification.
@en
P2093
John M Maris
P356
10.1097/01.MOP.0000150631.60571.89
P577
2005-02-01T00:00:00Z